Assertio Holdings | DEPO - Cost Of Sales


Assertio Holdings reported $8.89M in Cost of Sales for its fiscal quarter ending in June of 2024.





Cost Of Sales Change Date
ANI Pharmaceuticals USD 114.5M 8.38M Mar/2026
Assertio Holdings USD 8.89M 2.29M Jun/2024
Aurora Cannabis CAD 88.61M 30.53M Dec/2025
Cara Therapeutics USD 0 0 Mar/2025
Daiichi Sankyo JPY 118.28B 37.7B Dec/2025
Ironwood Pharmaceuticals USD 29.83M 560K Sep/2024
J&J USD 8.07B 103M Mar/2026
Knight Therapeutics CAD 82.22M 1.03M Dec/2025
Merck USD 2.94B 380M Mar/2026
Nektar Therapeutics USD 4.43M 5.3M Sep/2024
Omeros USD 33.16M 18.52M Jun/2024
Pfizer USD 4.59B 1.7B Mar/2026
Teva Pharmaceutical Industries USD 2.01B 46M Mar/2026